Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
PCVX
PCVX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PCVX News
Wall Street Analysts Adjust Ratings
Feb 26 2026
Benzinga
Vaxcyte Reports Q4 and Full-Year 2025 Financial Results and Business Update
Feb 25 2026
NASDAQ.COM
Vaxcyte Reports Q4 Losses and Cash Position
Feb 24 2026
seekingalpha
Vaxcyte Initiates Phase 3 Trial for VAX-31 Vaccine
Feb 12 2026
NASDAQ.COM
Vaxcyte Prices Public Offering at $550 Million
Jan 30 2026
Newsfilter
Vaxcyte Initiates Phase 3 Trials for VAX-31, Market Cap Around $7 Billion
Jan 23 2026
Benzinga
Vaxcyte Advances VAX-31 Vaccine with 95% Coverage for Adults
Jan 23 2026
NASDAQ.COM
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Jan 16 2026
Barron's
Vaxcyte CTO Sells 9,743 Shares Worth Approximately $454,891 Amidst Stock Decline
Jan 03 2026
NASDAQ.COM
Vaxcyte's CTO Sells 9,743 Shares Valued at Approximately $454,891
Jan 03 2026
Fool
This Pharmaceutical Stock Struggled Last Year, But One Analyst Believes It Could Surge 250%.
Dec 22 2025
Barron's
Mizuho's Lesser-Known Stock Choice for 2026: A Wall Street Favorite That Could See Its Value Triple
Dec 20 2025
CNBC
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Dec 11 2025
MarketWatch
Vaxcyte Administers Initial Doses to Patients in Phase 3 Trial of VAX-31 for Invasive Pneumococcal Disease and Pneumonia
Dec 08 2025
Yahoo Finance
Vaxcyte Initiates Phase 3 Trial for VAX-31 Vaccine, Aiming 95% Coverage
Dec 08 2025
Globenewswire
The Biotech Sector Is Stronger Than Investors Realize: Key Stocks to Monitor.
Dec 04 2025
Barron's
Show More News
